美沙拉嗪肠溶片对强直性脊柱炎患者TNF-α和IL-6的影响和临床意义

Influence and clinical significance of huidi mesalazine for concentrations of in sera TNF-α and IL-6 from patients with AS disease

目的探讨惠迪肠溶片对强直性脊柱炎患者血清肿瘤坏死因子和白细胞介素水平的影响,以评价惠迪肠溶片临床意义。方法采用自身前后对照,纳入患者口服惠迪肠溶片,每次2片,每日3次。测定比较用药前后血清TNF-α和IL-6含量。结果 AS患者经惠迪肠溶片治疗后,血清TNF-α、IL-6水平显著降低,差异有统计学意义(P<0.05)。结论惠迪肠溶片能降低强直性脊柱炎患者血清TNF-α、IL-6水平,从而抑制AS患者体内异常活跃的免疫水平,对AS有治疗作用。

Objective To study the effects of huidi mesalazine in patients with AS disease. Methods The concentrations of TNF- α and IL-6 in the sera of patients with AS disease were measured by the enzyme-linked immunosorbent assay. The patients were treated with huidi mesalazine for every two and three times a day. Results compared with the concentrations untreated, the concentrations of TNF- α and IL-6 in all patients were significantly lower （P 〈 0.05）. Conclusion Huidi mesalazine can reduce the concentrations of TNF- α and IL-6 in the sera of patients with AS disease.